Explore the dual pathways of IL-33
| Estimated time to read:
The following content is part of a paid sponsorship and is not an endorsement by CHEST nor does it reflect the views or opinions of CHEST.
Why might COPD remain uncontrolled in some patients? IL-33 is a key driver of COPD—it is a cytokine expressed in the lungs and is released in response to epithelial injury. Learn more about its 2 bioactive forms, a reduced form (IL-33 RED) and an oxidized form (IL-33 OX), which play distinct roles in driving inflammation and mucus dysfunction in COPD, respectively. Explore IL-33’s function and how these 2 forms activate dual pathways that may contribute to the pathogenesis of COPD.
Don’t miss out on an in-depth discussion with a leading expert about the duality of IL-33 in COPD. See below for event details.
Title: The Duality of IL-33 in COPD: Inflammation and Mucus Dysfunction
Date: October 20 at 2:00 p.m.-2:45 p.m.
Location: Exhibit Hall, Learning Theater 3
This is a non-CME event and does not qualify for CME or CE, or MOC credit. This event is not part of the official CHEST Annual Meeting 2026 conference sessions. This event is not an endorsement by CHEST and does not reflect the views or opinions of CHEST.
Still looking for more information about IL-33?
Stop by Booth #763 during CHEST 2026 or visit www.dualcopdburden.com to learn more and access additional resources.
CE=continuing education; CME=continuing medical education; COPD=chronic obstructive pulmonary disease; IL=interleukin; MOC=maintenance of certification.
©2026 AstraZeneca. All rights reserved.
US-115714 Last Updated 9/26
